Concerns about microplastics and their effect on human and environmental health are no longer confined to academic literature or environmental advocacy. On April 6, 2026, the U.S. Environmental Protection Agency (EPA) and the U.S. Department of Health and Human Services (HHS) elevated the issue in a way that makes it harder for the regulated community to address the issue of microplastics as largely academic or purely speculative. EPA has proposed to add microplastics, for the first time, as a priority contaminant group on the Drinking Water Contaminant Candidate List (CCL) 6 – Draft (draft Sixth Contaminant Candidate List or CCL 6) under the Safe Drinking Water Act (SDWA), while HHS launched the Systematic Targeting Of MicroPlastics (STOMP), a $144 million program focused on measuring, studying, and developing methods to remove microplastics and nanoplastics (MNP) from the human body. EPA expressly tied the move to the Trump Administration’s “Make America Healthy Again” (MAHA) agenda. This initiative was made a week after United We Eat, a nonpartisan initiative and platform, submitted a letter — signed by United We Eat and 38 other signatories — to EPA Administrator Lee Zeldin, urging him to protect the public from chemicals such as per- and polyfluoroalkyl substances (PFAS) and microplastics.
That matters because the Administration is beginning to frame microplastics less as a waste-management or marine-litter issue and more as a public-health and exposure-science issue. In The MAHA Report, issued by the White House in 2025, microplastics were identified alongside PFAS and other environmental exposures (as discussed in our June 2, 2025, blog) as part of the cumulative-exposure concerns potentially affecting children’s health (as discussed in our August 28, 2025, blog). The MAHA Report defined microplastics as fragments less than five millimeters in size, cited research on increasing concentrations in human brain tissue, and pointed to studies suggesting concern about endocrine-disrupting chemicals associated with microplastics.
This is a meaningful shift in framing. For years, microplastics policy discussions were often housed in debates over recycling, product stewardship, packaging, and marine pollution. MAHA’s emphasis moves the issue toward questions of bodily burden, chronic exposure, and health protection — more aligned with the arguments expressed by the European Union (EU). EPA’s April 2026 announcement reflects that move: EPA described the CCL as a tool that drives research, funding, and future regulatory decisions, while emphasizing that microplastics and pharmaceuticals were being elevated in response to public concern about contaminants in drinking water. The CCL 6 is available for public comment, and EPA has said that it specifically requests comments that focus on the draft and the process used to develop the draft.
At the same time, it is important to be precise about what EPA did — and did not do. Inclusion in the CCL 6 is not itself a drinking-water standard and does not immediately impose compliance obligations on public water systems or manufacturers. EPA states that contaminants on the CCL are not yet subject to proposed or promulgated National Primary Drinking Water Regulations but may require future regulation under the SDWA. EPA is taking comment on draft CCL 6 through June 5, 2026, and expects to issue in final CCL 6 later this year after Science Advisory Board consultation.
Still, companies in the chemical, plastics, consumer products, water, and waste sectors should not read that procedural point as a sign that nothing has changed. The practical significance of the April 2026 announcement is that microplastics have now moved into a clearer federal policy pipeline. EPA has formally signaled that the subject warrants focused scientific attention and possible future regulatory action, while HHS has committed federal research dollars to tools for measurement, source identification, and removal. That combination increases the odds that future debates will be more data-rich, more public-facing, and less a narrow, product-specific conversation.
MAHA’s reassertion of its agenda and “demands” for action may also affect the chemical regulatory policy space in more structural ways. First, it may accelerate the reframing of microplastics from an environmental externality to an exposure issue that can be discussed alongside PFAS, pharmaceuticals, endocrine disruptors, and children’s health. Second, it may increase pressure on agencies to explain inaction where detectable human exposure exists, even if dose-response science remains unsettled. Third, it may drive more interest in upstream questions — product composition, additives, degradation pathways, and lifecycle sources — rather than focusing only on downstream waste management. Pressure for action, even when information is “incomplete,” creeps nearer the approach to chemicals risk favored by the EU — the dreaded (by some) “precautionary principle” — not a policy approach expected from the current Administration.
There are no announced rules yet, and any such rules may be many years off into the future, but these are plausible regulatory consequences of the way EPA, HHS, and the Administration are now talking about the microplastics issue and how to regulate chemical exposure risks generally. This evolving posture creates both risk and uncertainty for regulated parties. Microplastics remain unusually difficult to address through conventional chemical-control frameworks because they are ubiquitous, heterogeneous, and often associated with a wide range of products, polymers, additives, and environmental pathways. The science is evolving, and even official statements accompanying the new federal actions emphasize research, measurement, and future decision-making, rather than immediate regulation. But once an issue is framed as a health-protection priority within a broader presidential agenda, it can influence rulemaking priorities, grant funding, interagency coordination, public messaging, and litigation narratives.
For industry, the message is not that sweeping federal microplastics restrictions are imminent. The message is that microplastics, along with exposure from other controversial chemicals and pesticides, have become harder to treat as a peripheral issue. Companies should expect closer scrutiny of product formulations, additives, degradation profiles, and claims about safety or sustainability. Companies should also expect advocates and plaintiffs’ lawyers to cite the Administration’s own language when arguing that microplastics are a recognized public health concern, even though the underlying science and regulatory endpoints remain fluid and in development. That tension — between expanding political salience and incomplete scientific consensus — is likely to define the next phase of microplastics policy.
The challenge for policymakers will be to avoid two familiar mistakes. One is overcorrection: moving from concern to restriction without a sufficiently clear scientific or statutory basis. The other is underreaction: treating uncertainty as a reason to defer all meaningful action while evidence, public attention, and legal pressure continue to build. EPA’s CCL 6 move and HHS’s STOMP initiative suggest that the Administration is trying to stake out a middle position for now — emphasizing measurement, prioritization, and future options, rather than immediate enforceable limits. Whether that balance holds will matter greatly for the chemical regulatory community.
In short, MAHA’s recent stance on microplastics and advocacy about other chemical and pesticide risks appears to be pushing the issues toward the center of federal health and environmental policy. For the chemical and pesticide industries, that does not yet mean a new compliance regime. It does mean, however, that microplastics, among other specific chemical exposures, are becoming a more salient part of the regulatory conversation around drinking water, cumulative exposure, product stewardship, and human-health risk — and that this conversation is now being driven from the top of the federal policy agenda rather than from the margins.
